CVS Health Corporation — CVS
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $78.99 | $100.27B | 207.9 | 12.2 | 39.5% | 6.1% | $2.66 3.4% | 1.4 |
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $268.7B | $7.2B | $5.48 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $292.1B | $8.0B | $6.00 | 8.7% | 11.5% | 9.5% |
| 2 | 2022-12-31 | $322.5B | $4.3B | $3.29 | 10.4% | -46.1% | -45.2% |
| 3 | 2023-12-31 | $357.8B | $8.3B | $6.49 | 10.9% | 93.6% | 97.3% |
| 4 | 2024-12-31 | $372.8B | $4.6B | $3.67 | 4.2% | -44.7% | -43.5% |
| 5 | TTM 2025-03-31 | $379.0B | $5.3B | $4.19 | 1.6% | 14.4% | 14.2% |
| 6 | Average | 7.2% | 5.7% | 6.5% |
EPS
Forecasts
Y/Y % Change
CVS Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 8.7% | 10.4% | 10.9% | 4.2% | 7.0% | 5.8% | 7.8% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 7 | 7 | |
| EPS Growth (%) | 11.5% | -46.1% | 93.6% | -44.7% | 82.1% | 8.3% | 17.4% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 10 | 10 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | Facilities / D&A ($) |
|---|---|---|---|
| 2021 | $292.1B | $235.5B | $4.5B |
| 2022 | $322.5B | $263.7B | $4.2B |
| 2023 | $357.8B | $299.0B | $4.4B |
| 2024 | $372.8B | $316.8B | $4.6B |
| TTM | $386.6B | $328.6B | $4.6B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|
| 2022 | 10.39 | 11.99 | -5.84 |
| 2023 | 10.95 | 13.36 | 3.36 |
| 2024 | 4.20 | 5.96 | 5.29 |
| TTM | 3.71 | 3.71 | 0.78 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2025-11-10 08:20 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
| Year | Prod Rev | Prod OI | Services Rev | Services OI | Total Rev | Total OI |
|---|---|---|---|---|---|---|
| 2022 | 226.6B | 0.00B | 9.68B | 0.00B | 236.3B | 0.00B |
| 2023 | 245.1B | 0.00B | 12.3B | 0.00B | 257.4B | 0.00B |
| 2024 | 231.5B | 0.00B | 16.2B | 0.00B | 247.8B | 0.00B |
| TTM | 249.7B | 0.00B | 14.9B | 0.00B | 264.6B | 0.00B |
| % of Total (TTM) | 94.4% | — | 5.6% | — | 100% | — |
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $258,343M |
| 1 | Cash | $11,787M |
| 2 | Total Liabilities | $180,792M |
| 3 | Total Debt | $82,724M |
| 4 | Total Equity | $77,379M |
| 5 | Debt to Equity Ratio | 1.07 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $66.57 | 4.4% | Nicks Growth: 5% Nick's Expected Margin: 2% FINVIZ Growth: 14% |
Nicks: 11 Finviz: 25 |
Nick's: 0.213 | 0.2 | 15.9 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $4.19 EPS | TTM | $44.59 | -33.0% | $103.13 | 54.9% |
| $6.11 EPS | 2025 | $65.03 | -2.3% | $150.39 | 125.9% |
| $6.97 EPS | 2026 | $74.18 | 11.4% | $171.55 | 157.7% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 12.63% | 5.16% | 11.45% | 5.29% | 7.22% | 0.81% | 39.54% | 6.09% | 100.0% | 88.0% |
| 3 Years | 12.63% | 5.16% | 11.45% | 5.29% | 7.22% | 0.81% | 39.54% | 6.09% | 100.0% | 88.0% |
| 5 Years | 12.63% | 5.16% | 11.45% | 5.29% | 7.22% | 0.81% | 39.54% | 6.09% | 100.0% | 88.0% |
| 10 Years | 12.63% | 5.16% | 11.45% | 5.29% | 7.22% | 0.81% | 39.54% | 6.09% | 100.0% | 88.0% |